Investigators studied whether changes in renal hyperfiltration status affects patient outcomes using a Korean population cohort of more than 4.5 million patients.

With investors and drugmakers increasingly eyeing the kidney disease space, a new company hopes to shed its underdog status ...

Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it will present data at the ...

Chronic kidney disease (CKD) is progressive and irreversible damage to your kidneys. The most common causes of CKD are high blood pressure and diabetes.

E-Poster No. 1325 About Akebia Therapeutics Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease.

References. Chronic kidney disease in the United States, 2023. Centers for Disease Control and Prevention. Updated May 15, 2024. Accessed November 13, 2024.

Chronic renal failure: Discovery of a crucial biomarker. ScienceDaily . Retrieved June 11, 2025 from www.sciencedaily.com / releases / 2025 / 05 / 250527124435.htm ...

CAMBRIDGE, Mass., May 27, 2025 (GLOBE NEWSWIRE) -- Akebia Therapeutics®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease ...